A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
Sponsor: CinDome Pharma, Inc.
A PHASE2 clinical study on Gastroparesis, this trial is completed. The trial is conducted by CinDome Pharma, Inc. and has accumulated 14 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CinDome Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .